xRead - Nonallergic Rhinitis (September 2025)

Clinical Reviews in Allergy & Immunology (2024) 67:40–46

43

Fig. 1 Study flow gram of the review following PRISMA guidelines

between the intervention and the outcome. This suggests that capsaicin exhibits superior efficacy when compared to placebo.

effects model was utilized to cope with the heterogeneity. The funnel plot (Fig. 4) of this analysis suggests that the included studies exhibit an acceptable level of bias. For tri als reporting therapeutic responders, we conducted a sec ond analysis using odds ratio and showing 95% confidence interval in Fig. 3.

Description of Other Outcomes

The efficacy of capsaicin treatment for nasal inflammatory disorders has been assessed using various methods, includ ing clinical symptom scores, nasal airway resistance (NAR), and molecular markers. In 2021, Zebda observed a signifi cant decrease in median change in optical density (OD) from baseline at 4 and 12 weeks in the intervention group, indicat ing a reduction in nasal airway obstruction. While 100% of patients initially met criteria for NAR diagnosis, only 55% and 40% met the criteria at 4 and 12 weeks, respectively, sug gesting a potential improvement in NAR [1]. In 2014, Van Gerven observed a borderline significant correlation between decreased TRPV1 expression and reduced VAS scores for

Discussion

Description of Primary Outcomes

Through figures presenting results of analyses which are both considered statistically significant ( p < 0.05), it’s obvi ous that capsaicin does well in enhancing TNSS or VAS of NAR patients at the end of studies. Studies reporting on the number of therapeutic responders have demonstrated an odds ratio greater than 1, indicating a positive correlation